18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer
Metrics: PDF 722 views | HTML 734 views | ?
Ana E. Brito1, Allan Santos1,2, André Deeke Sasse3, Cesar Cabello4, Paulo Oliveira5, Camila Mosci1, Tiago Souza1, Barbara Amorim1, Mariana Lima1,2, Celso D. Ramos1,2, Elba Etchebehere1,2
1Nuclear Medicine Division, Campinas State University (UNICAMP), SP, Brazil
2MND Campinas, Campinas, SP, Brazil
3Department of Internal Medicine, Campinas State University (UNICAMP), SP, Brazil
4Department of Gynecology and Obstetrics, Campinas State University (UNICAMP), SP, Brazil
5Department of Statistics, Campinas State University (UNICAMP), SP, Brazil
Elba Etchebehere, email: firstname.lastname@example.org
Keywords: fluoride-PET/CT, NaF PET/CT, breast cancer, skeletal tumor burden, bone metastases
Received: February 01, 2017 Accepted: March 14, 2017 Published: March 21, 2017
Purpose: In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease.
Results: Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p < 0.0001) and progression free-survival (p < 0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448).
Materials and Methods: We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months.
Conclusions: 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.